Please use this identifier to cite or link to this item:
Title: Antiplatelet Drugs for Neurointerventions: Part 1 Clinical Pharmacology.
Austin Authors: Pearce, Samuel;Maingard, Julian T;Li, Kenny;Kok, Hong Kuan;Barras, Christen D;Russell, Jeremy H ;Hirsch, Joshua A;Chandra, Ronil V;Jhamb, Ash;Thijs, Vincent N ;Brooks, Duncan Mark ;Asadi, Hamed 
Affiliation: Department of Neurosurgery, Austin Health, Heidelberg, Victoria, Australia
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
Interventional Neuroradiology Service, Department of Radiology, Austin Health, Heidelberg, Victoria, Australia
Interventional Neuroradiology, St Vincent's Hospital, Melbourne, Victoria, Australia
Interventional Neuroradiology Unit, Monash Imaging, Monash Health, Melbourne, Victoria, Australia
School of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Victoria, Australia
Interventional Radiology Service, Department of Radiology, Northern Hospital, Melbourne, Victoria, Australia
South Australian Institute of Health and Medical Research, Adelaide, South Australia, Australia
School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Department of Imaging, Monash University, Melbourne, Victoria, Australia
Stroke Division, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia
School of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Issue Date: Sep-2020 2020-05-18
Publication information: Clinical Neuroradiology 2020; 30(3): 425-433
Abstract: The development of endovascular treatment for intracranial aneurysms has established new techniques such as balloon and stent-assistance, flow diversion and endosaccular occlusion devices. Antiplatelet treatment is an important aspect to reduce risk of thrombus formation on microcatheters and implanted devices when utilizing these methods. It is particularly relevant for flow diverting stents to prevent early and late stent thrombosis. Consideration of platelet physiology and appropriate selection of antiplatelet medication is important as platelet dysfunction drives many of the pathological processes and complications of neurointerventional procedures. Part one of this review focuses on basic platelet physiology, pharmacology of common antiplatelet medications and future directions and therapies. Part two focuses on clinical applications and evidence-based therapeutic regimens.
DOI: 10.1007/s00062-020-00910-5
ORCID: 0000-0003-3692-120X
PubMed URL: 32424668
Type: Journal Article
Subjects: Aneurysm
Flow diverting
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.